Hematopoietic stem cell transplantation and cell therapy

Added value in the treatment of hematopoietic patients

Published

2023-04-19

How to Cite

Maldonado Guerrero, B. (2023). Hematopoietic stem cell transplantation and cell therapy: Added value in the treatment of hematopoietic patients. Oncology Journal (Ecuador), 33(1), 103–106. https://doi.org/10.33821/682

Authors

  • Bella Maldonado Guerrero Unidad de Trasplante de Médula Ósea, SOLCA - Guayaquil.

DOI:

https://doi.org/10.33821/682

Keywords:

Bone Marrow Transplantation, Bone Marrow Neoplasms, Cord Blood Stem Cell Transplantation

Abstract

Hematopoietic stem cell transplantation has become a curative and disease-free survival option than those achieved with other therapeutic modalities in specific congenital or tumor pathologies. At the beginning of 2006, the project for the creation of the Hematopoietic Stem Cell Transplant Unit of the Hospital de SOLCA – Guayaquil was designed. In June 2006, the Bone Marrow Transplant Unit (UTMO) began the first transplants, one autologous and the other allogeneic. Since then, 375 hematopoietic progenitor transplants have been performed, of which 166 have been allogeneic, 147 with hematopoietic progenitors obtained from peripheral blood or bone marrow itself, and 19 with cells obtained from umbilical cord blood, as well as 209 autologous transplants. An expansion project has been designed that includes an infrastructure with 20 rooms for hospitalization and a larger area for cell manipulation with complementary equipment, which will make it possible to increase the portfolio of services, namely: the option of haploidentical allogeneic transplantation and specific adoptive T-cell immunotherapy procedures.

Downloads

Download data is not yet available.

Most read articles by the same author(s)